Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

23 citing papers in PubMed, 52 citations in OpenAlex.

1. Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms.Current hematologic malignancy reports · 2026
   Review
2. Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations.Cancers · 2024
   Review
3. Trans-vaccenic acid reprograms CD8Nature · 2023
   Article
4. Lupus Nephritis: New and Emerging Biologic and Targeted Therapies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
   Review
5. New approaches to tackle cytopenic myelofibrosis.Hematology. American Society of Hematology. Education Program · 2022
   Article
6. Ruxolitinib ameliorates progressive anemia and improves survival during episodes of emergency granulopoiesis in Fanconi CExperimental hematology · 2022
   Article
7. A screen of repurposed drugs identifies AMHR2/MISR2 agonists as potential contraceptives.Proceedings of the National Academy of Sciences of the United States of America · 2022
   Article
8. Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2Blood cancer journal · 2022
   Article
9. Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2.Journal of controlled release : official journal of the Controlled Release Society · 2021
   Review
10. Structural Basis of Inhibition of DCLK1 by Ruxolitinib.International journal of molecular sciences · 2021
    Article
11. Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections.Nano today · 2021
    Review
12. Recent Advances in Molecular Diagnosis and Prognosis of Childhood B Cell Lineage Acute Lymphoblastic Leukemia (B-ALL).Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2021
    Review
13. Immune response and possible therapeutics in COVID-19.RSC advances · 2020
    Review
14. Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
15. Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials.International journal of molecular sciences · 2020
    Review
16. Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells.International journal of radiation biology · 2020
    Article
17. Canadian consensus: a new systemic treatment algorithm for advancedCurrent oncology (Toronto, Ont.) · 2020
    Article
18. Norovirus Replication in Human Intestinal Epithelial Cells Is Restricted by the Interferon-Induced JAK/STAT Signaling Pathway and RNA Polymerase II-Mediated Transcriptional Responses.mBio · 2020
    Article
19. The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature.The Yale journal of biology and medicine · 2020
    Review
20. [Biobanking requirements from the perspective of the clinician : Experiences in hematology and oncology].Der Pathologe · 2018
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 2 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as